240 related articles for article (PubMed ID: 9855414)
1. A phased approach to clinical testing: criteria for progressing from Phase I to Phase II to Phase III studies.
André FE; Foulkes MA
Dev Biol Stand; 1998; 95():57-60. PubMed ID: 9855414
[TBL] [Abstract][Full Text] [Related]
2. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
3. Monitoring and safety assessment in Phase I to III clinical trials.
Fescharek R; Nicolay U; Arras-Reiter C
Dev Biol Stand; 1998; 95():203-9. PubMed ID: 9855433
[TBL] [Abstract][Full Text] [Related]
4. A clinical development paradigm for cancer vaccines and related biologics.
Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
[TBL] [Abstract][Full Text] [Related]
5. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
6. Clinical trial design in metastatic breast cancer: a commentary.
Levine M
Can J Oncol; 1995 Dec; 5 Suppl 1():40-2. PubMed ID: 8853523
[TBL] [Abstract][Full Text] [Related]
7. New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development.
Kamath AT; Fruth U; Brennan MJ; Dobbelaer R; Hubrechts P; Ho MM; Mayner RE; Thole J; Walker KB; Liu M; Lambert PH; ;
Vaccine; 2005 May; 23(29):3753-61. PubMed ID: 15893612
[TBL] [Abstract][Full Text] [Related]
8. Bridging studies.
Fritzell B
Dev Biol Stand; 1998; 95():181-8. PubMed ID: 9855430
[TBL] [Abstract][Full Text] [Related]
9. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.
Knuf M; Habermehl P; Faber J; Bock HL; Sänger R; Bogaerts H; Clemens R; Schuind A; du Prel JB; Schmitt HJ
Vaccine; 2006 Jul; 24(27-28):5627-36. PubMed ID: 16740348
[TBL] [Abstract][Full Text] [Related]
10. [The malaria vaccine candidate RTS,S/AS is in phase III clinical trials].
Cohen J; Benns S; Vekemans J; Leach A
Ann Pharm Fr; 2010 Nov; 68(6):370-9. PubMed ID: 21073995
[TBL] [Abstract][Full Text] [Related]
11. Dose selection in seamless phase II/III clinical trials based on efficacy and safety.
Kimani PK; Stallard N; Hutton JL
Stat Med; 2009 Mar; 28(6):917-36. PubMed ID: 19152231
[TBL] [Abstract][Full Text] [Related]
12. Measuring protection: efficacy versus effectiveness.
Fedson DS
Dev Biol Stand; 1998; 95():195-201. PubMed ID: 9855432
[TBL] [Abstract][Full Text] [Related]
13. Alternative strategies in drug development: clinical pharmacological aspects.
Kuhlmann J
Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
[TBL] [Abstract][Full Text] [Related]
14. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
Lunsford LD; Flickinger JC; Larson D
Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
[TBL] [Abstract][Full Text] [Related]
15. The Challenge of Developing New Therapies for Childhood Cancers.
Balis FM
Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
[TBL] [Abstract][Full Text] [Related]
16. Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials.
Mosolits S; Nilsson B; Mellstedt H
Expert Rev Vaccines; 2005 Jun; 4(3):329-50. PubMed ID: 16026248
[TBL] [Abstract][Full Text] [Related]
17. Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis.
Farahani P; Levine M; Gaebel K; Thabane L
Can J Clin Pharmacol; 2005; 12(3):e254-63. PubMed ID: 16278497
[TBL] [Abstract][Full Text] [Related]
18. [The quest for an HIV vaccine].
Girard MP
Bull Acad Natl Med; 2005 May; 189(5):831-44; discussion 844. PubMed ID: 16433455
[TBL] [Abstract][Full Text] [Related]
19. Drug development: from concept to marketing!
Tamimi NA; Ellis P
Nephron Clin Pract; 2009; 113(3):c125-31. PubMed ID: 19729922
[TBL] [Abstract][Full Text] [Related]
20. Epidemiological factors in clinical trial design.
Wassilak S
Dev Biol Stand; 1998; 95():75-83. PubMed ID: 9855417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
